Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05096884 · ClinicalTrials.gov registry record · Early Phase 1
Post-Acute Sequelae of Coronavirus-19 (COVID-19) With Dyspnea on Exertion And Associated TaChycardia TrEatment Study
A Early Phase 1 study, sponsored by Hackensack Meridian Health.
- Terminated
- Registry status
- Early Phase 1
- Development phase
- 14
- Enrollment target
NCT05096884 is a Early Phase 1 study that was terminated before completion, run by Hackensack Meridian Health. The registered enrollment target is 14 participants.
The verdict
NCT05096884, a Early Phase 1 study, was terminated before completion, sponsored by Hackensack Meridian Health.
- TERMINATED
- Registry status
- Early Phase 1
- Development phase
- 14 participants
- Enrollment target
Study Summary
Most patients with acute COVID-19 (Coronavirus 19) recover within weeks, however a significant number of individuals will develop the post-acute COVID 19 syndrome (PASC). As of July 2021, the post COVID syndrome qualifies as a disability under the Americans with Disabilities Act. The symptoms which comprise this condition are highly variable and often extraordinarily debilitating. They may be distinct from the initial presentation or may mimic those which defined the initial infection. The post COVID syndrome can be diagnosed when symptoms persist longer than 3 months and may extend to beyond one year. There are risks for permanent levels of disability. Patients who seemingly did not have active COVID-19 symptoms in the days following infectious exposure may also develop post Covid syndromes. These syndromes are considered to constitute a distinct clinical entity which has of yet no clearly defined pathogenic mechanism or validated treatment algorithms. International investigative efforts are now underway to determine who might develop the post COVID syndrome, it's long term consequences and how best to treat its many problematic symptoms.
Interventions
- DRUG Metoprolol Succinate
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 14 participants |
| Start Date | 2022-03-23 |
| Est. Completion | 2023-09-12 |
| Phase | Early Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05096884
The ClinicalTrials.gov registry entry for NCT05096884 describes a study currently listed as terminated, categorized as Early Phase 1. The registered enrollment target is 14 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Hackensack Meridian Health, which has 90 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Metoprolol Succinate is the first listed.
NCT05096884 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05096884 about?
NCT05096884 is a clinical study titled "Post-Acute Sequelae of Coronavirus-19 (COVID-19) With Dyspnea on Exertion And Associated TaChycardia TrEatment Study". Most patients with acute COVID-19 (Coronavirus 19) recover within weeks, however a significant number of individuals will develop the post-acute COVID 19 syndrome (PASC). As of July 2021, the post COVID syndrome qualifies as a disability under the Americans with Disabilities Act. The symptoms which ...
What is the current status of trial NCT05096884?
This trial is currently terminated. It is a Early Phase 1 study. The enrollment target is 14 participants. The study started on 2022-03-23. Estimated completion is 2023-09-12.
What interventions are being tested in trial NCT05096884?
The interventions under investigation include: Metoprolol Succinate (DRUG).
Who is sponsoring clinical trial NCT05096884?
This trial is sponsored by Hackensack Meridian Health, which has 90 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.